The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Open accessAbstract
HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D. However, one of these lesions had progressed on evaluation 9 months after therapy. The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule. The loss of expression of this molecule provided a direct mechanism of tumor immune evasion. Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C*08:02.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This approach has shown efficacy in colon cancer and NSCLC patients with mutant KRAS G12D and HLA-C*08:02 expression [88].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tumors with mutant KRAS can express neoantigen fragments containing the oncogenic driver mutation on the major histocompatibility complex [88,89].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
In the citing paper
“CD8+ TILs and TCRs in CD4+ T cells have been found to specifically recognize KRAS-related mutations, which can be further used to engineer T cells.604,605”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [604]
In the citing paper
“As noted above, peptides derived from KRASG12 variants193,194, and also from KRASQ61H/L/R (ref.198), have been demonstrated to be presented on the surface of malignant cells by various MHC I (HLA-A) molecules.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“ACT with these specific TILs resulted in regression of all seven pulmonary metastases in a patient with KRASG12D-mutant CRC from whom they had been isolated193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Notably, loss of MHC was identified as an immune-evasion mechanism in a tumour that progressed 9 months after TIL infusion193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Endogenous immune responses against KRAS-mutant cancer cells were first described in 2016 by Tran et al.193, who identified CD8+ TILs with T cell receptors (TCRs) that recognize MHC I (HLA-C*08:02)-presented peptide neoepitopes derived from KRASG12D.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Using CD8+ T cells that were reactive to KRASG12D mutant, a patient with CRC experienced prolonged partial response [64].”
From KRAS, a New Target for Precision Medicine in Colorectal Cancer? (2024) · cites this paper as [64]
In the citing paper
“It was found that CD8+ T cells, possessing HLA-C08:02-restricted T-cell receptors, specifically recognize the mutant KRASG12D.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Following the intravenous administration of expanding TCRs in an ex vivo environment, a complete response was observed in lung lesions, resulting in prolonged PFS.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“A recent publication presented the relationship between the KRASG12D mutation and TCRs in a patient diagnosed with metastatic mCRC with lung metastasis [106].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Despite the rarity of HLA-C*08:02, this study demonstrated the promise of T-cell–based immunotherapy for targeting KRASG12D and HLA-C*08:02.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“Tran and colleagues described a case of a patient with metastatic colorectal cancer treated with autologous T cells specific for mutant KRASG12D, which was restricted to the major histocompatibility complex class I allele HLA-C*08:02 (44).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“The anti-tumor activity of ICB has been shown to depend on CD8+ T cell, HLA class I–dependent immune activity (34–36).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208
Self-citationCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625
Self-citationAllele-specific copy number analysis of tumors
Loo, P. V., Nord, S., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,192
Flagged first, then by citations
Cited by
Sorted by citations
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Immunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Organoid modeling of the tumor immune microenvironment
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,570
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
Melief, C. J. M., van Hall, T., Arens, R., OSSENDORP, F. A., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,192
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Self-citationClinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T. B., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 1,018
Neoantigen-directed immune escape in lung cancer evolution
The TRACERx consortium, Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M., Reading, J. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1032-7 · Cited by 946
Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Bakir, M. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 967
Macromolecular modeling and design in Rosetta: recent methods and frameworks
Leman, J. K., Weitzner, B. D., Lewis, S. M., Adolf-Bryfogle, J., Alam, N., Alford, R. F., Aprahamian, M., Baker, D., Barlow, K. A., Barth, P., et al. (2020) · Nature Methods · doi:10.1038/s41592-020-0848-2 · Cited by 888
Tumor-infiltrating lymphocytes in the immunotherapy era
Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 914
Martinez, M. C., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 865
Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787
Zacharakis, N., Chinnasamy, H., Black, M. A., Xu, H., Lu, Y., Zheng, Z., Pasetto, A., Langhan, M. M., Shelton, T. E., Prickett, T. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0040-8 · Cited by 786
Self-citationGenetics and biology of prostate cancerPreprint
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 814
Neoantigen vaccine: an emerging tumor immunotherapy
Miao, P., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., Guo, C. J., Wu, S., Li, Y., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1055-6 · Cited by 711
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674
Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
Doroshow, D. B., Sanmamed, M. F., Hastings, K., Politi, K. A., Rimm, D. L., Chen, L., Melero, I., Schalper, K. A., & Herbst, R. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1538 · Cited by 666
Resolving genetic heterogeneity in cancer
Turajlic, S., Sottoriva, A., Graham, T. A., & Swanton, C. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0114-6 · Cited by 675
T cell receptor (TCR) signaling in health and disease
Shah, K., Al-Haidari, A. A., Sun, J., & Kazi, J. U. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00823-w · Cited by 687
Genetic and biological hallmarks of colorectal cancerPreprint
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 617
Schumacher, T. N., Scheper, W., & Kvistborg, P. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 587
Advances in cancer immunotherapy 2019 – latest trends
Krüger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., Ormanns, S., Schuebbe, G., Renz, B. W., D’Haese, J. G., Schlößer, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1266-0 · Cited by 564
Identification of neoantigens for individualized therapeutic cancer vaccines
Lang, F., Schrörs, B., Löwer, M., Türeci, Ö., & Şahin, U. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00387-y · Cited by 569
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.016 · Cited by 548
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
Krishna, S., Lowery, F. J., Copeland, A. R., Bahadiroglu, E., Mukherjee, R., Jia, L., Anibal, J., Sachs, A., Adebola, S. O., Gurusamy, D., et al. (2020) · Science · doi:10.1126/science.abb9847 · Cited by 546
Self-citationWells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.015 · Cited by 538
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer
Leidner, R. S., Silva, N. S., Huang, H., Sprott, D. E., Zheng, C., Shih, Y.-P., Leung, A., Payne, R., Sutcliffe, K., Cramer, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119662 · Cited by 527
Self-citationPicard, E., Verschoor, C. P., Grace, W. K., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00369 · Cited by 533
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Zappasodi, R., Merghoub, T., & Wolchok, J. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.005 · Cited by 525
Orth, M., Metzger, P., Gerum, S., Mayerle, J. V., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 523
CD8+ T Cell Exhaustion in Cancer
Dolina, J. S., Budimir, N., Thomas, G. D., & Salek‐Ardakani, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.715234 · Cited by 504
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482
George, S., Miao, D., Demetri, G. D., Adeegbe, D. O., Rodig, S. J., Shukla, S. A., Lipschitz, M., Amin‐Mansour, A., Raut, C. P., Carter, S. L., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.001 · Cited by 481
Wu, M., Huang, Q., Xie, Y., Wu, X., Ma, H., Zhang, Y., & Xia, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01242-2 · Cited by 484
Immunotherapy and Prevention of Pancreatic Cancer
Morrison, A. H., Byrne, K. T., & Vonderheide, R. H. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.04.001 · Cited by 475
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449
Self-citationJiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 456
The Emerging Landscape of Immune Cell Therapies
Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 451
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443
Self-citationTCR-engineered T cell therapy in solid tumors: State of the art and perspectives
Baulu, E., Gardet, C., Chuvin, N., & Depil, S. (2023) · Science Advances · doi:10.1126/sciadv.adf3700 · Cited by 474
Macrophages at the interface of the co-evolving cancer ecosystem
Kloosterman, D. J., & Akkari, L. (2023) · Cell · doi:10.1016/j.cell.2023.02.020 · Cited by 447
Creelan, B., Wang, C., Teer, J. K., Toloza, E. M., Yao, J., Kim, S., Landin, A. M., Mullinax, J. E., Saller, J. J., Saltos, A. N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01462-y · Cited by 440
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
Immunotherapy in colorectal cancer: current achievements and future perspective
Fan, A., Wang, B., Wang, X., Nie, Y., Fan, D., Zhao, X., & Lu, Y. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.64077 · Cited by 425
Self-citationEnhancing anti-tumour efficacy with immunotherapy combinations
Meric‐Bernstam, F., Larkin, J., Tabernero, J. M., & Bonini, C. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32598-8 · Cited by 432
Organoid Models of Tumor Immunology
Yuki, K., Cheng, N., Nakano, M., & Kuo, C. J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.010 · Cited by 418
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Şahin, İ. H., Akce, M., Alese, O. B., Shaib, W. L., Lesinski, G. B., El‐Rayes, B. F., & Wu, C. S.-Y. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0599-y · Cited by 404
Trujillo, J., Sweis, R. F., Bao, R., & Luke, J. J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0277 · Cited by 396
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Nevala-Plagemann, C., Hidalgo, M. M., & Garrido‐Laguna, I. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0281-6 · Cited by 403
CAR T Cells and T-Cell Therapies for Cancer
Brudno, J. N., Maus, M. V., & Hinrichs, C. S. (2024) · JAMA · doi:10.1001/jama.2024.19462 · Cited by 412
Emerging Cellular Therapies for Cancer
Guedan, S., Ruella, M., & June, C. H. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041407 · Cited by 394
Tumor neoantigens: from basic research to clinical applications
Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 401
The Immunoscore: Colon Cancer and Beyond
Angell, H. K., Bruni, D., Barrett, J. C., Herbst, R., & Galon, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1851 · Cited by 399
Targeting a neoantigen derived from a common TP53 mutation
Hsiue, E. H.-C., Wright, K. M., Douglass, J., Hwang, M. S., Mog, B. J., Pearlman, A. H., Paul, S., DiNapoli, S. R., Konig, M. F., Wang, Q., et al. (2021) · Science · doi:10.1126/science.abc8697 · Cited by 367
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
Singhal, A., Li, B. T., & O'Reilly, E. M. (2024) · Nature Medicine · doi:10.1038/s41591-024-02903-0 · Cited by 380
Lynn, G. M., Sedlik, C., Baharom, F., Zhu, Y., Ramirez-Valdez, R. A., Coble, V. L., Tobin, K. K. S., Nichols, S. R., Itzkowitz, Y., Zaidi, N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0390-x · Cited by 351
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 337
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
Bulik-Sullivan, B. K., Busby, J., Palmer, C. D., Davis, M. J., Murphy, T., Clark, A., Busby, M., Duke, F. F., Yang, A., Young, L., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4313 · Cited by 317
Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
Taylor, B. C., & Balko, J. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844866 · Cited by 326
Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells
Miao, Y., Yang, H., Levorse, J., Yuan, S., Polak, L., Sribour, M., Singh, B., Rosenblum, M. D., & Fuchs, E. (2019) · Cell · doi:10.1016/j.cell.2019.03.025 · Cited by 299
Idos, G., Kwok, J., Bonthala, N. N., Kysh, L., Gruber, S. B., & Qu, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-60255-4 · Cited by 292
Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers
Parkhurst, M. R., Robbins, P. F., Tran, E., Prickett, T. D., Gartner, J. J., Jia, L., Ivey, G. D., Li, Y. F., El‐Gamil, M., Lalani, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1494 · Cited by 292
Self-citationImmunotherapy, Inflammation and Colorectal Cancer
Lichtenstern, C. R., Ngu, R. K., Shalapour, S., & Karin, M. (2020) · Cells · doi:10.3390/cells9030618 · Cited by 296
Non-viral precision T cell receptor replacement for personalized cell therapy
Foy, S. P., Jacoby, K., Bota, D. A., Hunter, T., Pan, Z., Stawiski, E. W., Ma, Y., Lu, W., Peng, S., Wang, C. L., et al. (2022) · Nature · doi:10.1038/s41586-022-05531-1 · Cited by 301
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
Paulson, K. G., Voillet, V., McAfee, M. S., Hunter, D. S., Wagener, F. D., Perdicchio, M., Valente, W. J., Koelle, S., Church, C. D., Vandeven, N. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06300-3 · Cited by 293
Liu, C., Zheng, S., Jin, R., Wang, X., Wang, F., Zang, R., Xu, H., Lu, Z., Huang, J., Lei, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.027 · Cited by 288
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Shafer, P. W., Somes, L. K., & Hoyos, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835762 · Cited by 292
Doran, S. L., Stevanović, S., Adhikary, S., Gartner, J. J., Jia, L., Kwong, M. L. M., Faquin, W. C., Hewitt, S. M., Sherry, R. M., Yang, J. C.-H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02424 · Cited by 283
Self-citationNeoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Malekzadeh, P., Pasetto, A., Robbins, P. F., Parkhurst, M. R., Paria, B. C., Jia, L., Gartner, J. J., Hill, V. K., Yu, Z., Restifo, N. P., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123791 · Cited by 274
Self-citationPersonalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer
Ding, Z., Li, Q., Zhang, R., Xie, L., Shu, Y., Gao, S., Wang, P., Su, X., Qin, Y., Wang, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00448-5 · Cited by 272
Pant, S., Wainberg, Z. A., Weekes, C. D., Furqan, M., Kasi, P. M., Devoe, C. E., Leal, A. D., Chung, V., Basturk, O., VanWyk, H., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02760-3 · Cited by 267
Promises and challenges of adoptive T-cell therapies for solid tumours
Morotti, M., Albukhari, A., Alsaadi, A., Artibani, M., Brenton, J. D., Curbishley, S. M., Dong, T., Dustin, M. L., Hu, Z., McGranahan, N., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01353-6 · Cited by 278
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development
de Olza, M. O., Rodrigo, B. N., Zimmermann, S., & Coukos, G. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30234-5 · Cited by 262
mRNA vaccines in disease prevention and treatment
Zhang, G., Tang, T., Chen, Y., Huang, X., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01579-1 · Cited by 273
Translational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 255
Clinical cancer immunotherapy: Current progress and prospects
Liu, C., Yang, M., Zhang, D., Chen, M., & Zhu, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961805 · Cited by 261
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay
Beaubier, N. T., Tell, R. W., Lau, D., Parsons, J., Bush, S., Perera, J. F., Sorrells, S., Baker, T., Chang, A. L., Michuda, J., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26797 · Cited by 251
Montesion, M., Murugesan, K., Jin, D. X., Sharaf, R., Sánchez, N., Guria, A., Minker, M., Li, G., Fisher, V. A., Sokol, E. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0672 · Cited by 253
Christenson, E. S., Jaffee, E. M., & Azad, N. S. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30795-8 · Cited by 245
Developing neoantigen-targeted T cell–based treatments for solid tumors
Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 241
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
Chen, F., Zou, Z., Du, J., Su, S., Shao, J., Meng, F., Yang, J. D., Xu, Q., Ding, N., Yang, Y., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci99538 · Cited by 233
Metadata
- Authors
- Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., Kriley, I. R., & Rosenberg, S. A.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-08
- Volume
- 375
- Issue
- 23
- Pages
- 2255-2262
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5178827
- OpenAlex
- W2559953355
- Cited by
- 1,368
- References
- 27
- Citations by year
- 2026: 96 · 2025: 132 · 2024: 129 · 2023: 162 · 2022: 162 · 2021: 183 · 2020: 149 · 2019: 134 · 2018: 118 · 2017: 98 · 2016: 3
- FWCI
- 71.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01BC010984)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- tumor-infiltrating lymphocytes, mutant KRAS, KRAS G12D, CD8+ T cells, tumor immune evasion, MHC class I loss, cancer immunotherapy
- MeSH terms
- Female, Flow Cytometry, Humans, Lung, Lung Neoplasms, Middle Aged, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), CD8-Positive T-Lymphocytes, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
